NL-OMON29769
Completed
Not Applicable
ong-term follow-up and prognosis of patients with ulnar neuropathy at the elbow in which the electrodiagnostic study shows a motor conduction block of more than 50% - prognosis of ulnar neuropathy with an severe motor conduction block
Sint Elisabeth Ziekenhuis0 sites80 target enrollmentTBD
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- nerve at elbow
- Sponsor
- Sint Elisabeth Ziekenhuis
- Enrollment
- 80
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Every patient with proven ulnar neuropathy at the elbow with at electrodiagnostic testing a motor conduction block of the abductor digiti minimi (ADM) and the musculus interosseus I (MII) of \>\= 50%.
- •Informed consent
Exclusion Criteria
- •\* Acute trauma origin of the ulnar neuropathy
- •\* History of a polyneuropathy
- •\* Findings of polyneuropathy during physical examination.
- •\* Genetically proven hereditary neuropathy with liability to pressure palsies
- •\* Alcohol\-abuse, chemotherapy
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Phase 2
Short and long-term outcome of patients undergoing pancreaticoduodenectomy - a single institute prospective cohort studyPeri-ampullar tumorJPRN-UMIN000052755Kobe City Medical Center General Hospital40
Active, not recruiting
Phase 1
A long-term follow-up study for patients treated with Galapagos CAR T cell therapiesRelapsed/refractory B-Cell non-Hodgkin lymphoma, Relapsed or refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL), Relapsed/refractory multiple myelomaMedDRA version: 21.0Level: LLTClassification code: 10051812Term: Small cell lymphocytic lymphoma Class: 10029104MedDRA version: 20.0Level: HLGTClassification code: 10025320Term: Lymphomas non-Hodgkin's B-cell Class: 10029104MedDRA version: 21.0Level: LLTClassification code: 10008976Term: Chronic lymphocytic leukemia Class: 10029104Therapeutic area: Diseases [C] - Neoplasms [C04]CTIS2023-510173-34-00Galapagos300
Not yet recruiting
Not Applicable
ong-Term Follow-Up of Patients who have received an Autologous Antigen-Specific Chimeric Antigen Receptor T Regulatory Cell Therapy (TX200-TR101) in a prior clinical study.Allograft rejectionRenal transplant rejection1002766510029149NL-OMON56013Sangamo Therapeutics France SAS8
Active, not recruiting
Phase 1
ong-Term Follow-Up of Patients who have received an Autologous Antigen-Specific Chimeric Antigen Receptor T Regulatory Cell Therapy (CAR- Treg therapy, TX200-TR101) in a prior clinical study.Prevention of immune mediated allograft rejection in patients with end-stage renal disease (ESRD) who are tissue typed as HLA-A*02 negative and have received a kidney transplant from an HLA-A*02 positive living donor.MedDRA version: 21.1Level: LLTClassification code 10050436Term: Prophylaxis against renal transplant rejectionSystem Organ Class: 10042613 - Surgical and medical proceduresTherapeutic area: Body processes [G] - Immune system processes [G12]EUCTR2022-002440-40-DESangamo Therapeutics France SAS15
Active, not recruiting
Phase 1
A study to evaluate the long-term safety of patients with advanced lymphoid malignancies who have been previously administered with UCART19Advanced lymphoid malignanciesMedDRA version: 20.0Level: LLTClassification code 10060390Term: Leukaemia lymphoblastic acuteSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2016-000297-38-BEInstitut de Recherches Internationales Servier (I.R.I.S)200